Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.

European journal of cancer (Oxford, England : 1990) - 1 May 2021

Krishnamurthy Nithya, Goodman Aaron M, Barkauskas Donald A, Kurzrock Razelle

Abstract excerpt

BACKGROUND: STK11 is an important tumour suppressor gene reported to confer immunotherapy resistance in non-small-cell lung cancers (NSCLC) especially in the presence of KRAS co-alterations. METHODS: This study analysed 4446 patients for whom next-generation sequencing of tissue and/or circulating tumour DNA (ctDNA) had been performed. RESULTS: Overall, 60 of 4446 tumours (1.35%) harboured STK11 alterations....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Follow-Up Studies

Share to Immunotherapy

Share to Neoplasms

Share to Protein Serine-Threonine Kinases

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 33744718
DOI: 10.1016/j.ejca.2021.01.050
PMCID: PMC10344467

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.PMID 33744718Read ↗

Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.Semantic proximity Read ↗

Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.Semantic proximity Read ↗

A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung CancerSemantic proximity Read ↗

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.Semantic proximity Read ↗

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.Semantic proximity Read ↗

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.Semantic proximity Read ↗

Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.Semantic proximity Read ↗

Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.Semantic proximity Read ↗

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.Semantic proximity Read ↗

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.